Former FDA Commissioner Frank Young Passes Away At 88
Executive Summary
From the approval of AZT to the generic drug scandal, Frank Young oversaw many seminal events at US FDA while commissioner from 1984 to 1989. After leaving the agency, he managed the approval of the NDA for Braeburn's opioid dependence drug Probuphine. Young passed away following a short bout with cancer.
You may also be interested in...
Keeping Track: A Good Week For Biologics And Probuphine, Less So For Eteplirsen And ZS-9
The latest drug development news and highlights from our FDA Performance Tracker.
Life After White Oak: Hamburg’s Predecessors Offer Glimpse At Where Pharma Might See Her Again
In interviews with “The Pink Sheet,” the last half-dozen FDA commissioners discuss crafting policy on Capitol Hill, building start-up biotechs, consulting and serving on industry boards.
FDA Rejects Titan’s Probuphine Despite Positive Panel Vote
FDA’s “complete response” letter for abuse-resistant buprenorphine for opioid dependence follows an advisory committee that aired concerns about efficacy and adequate dosing, as well as questioning the proposed Risk Evaluation and Mitigation Strategy.